Catabasis Pharmaceuticals Inc., of Cambridge, Mass., reported that all three doses of its experimental Duchenne muscular dystrophy (DMD) drug CAT-1004 tested during the first part of a phase I/II trial were generally well tolerated with no safety signals observed.